Pfizer - 52 Year Stock Split History | PFE

Stock split history for Pfizer since 1972. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Pfizer Annual Stock Splits
Pfizer Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $146.038B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.145B 74.49
Novo Nordisk (NVO) Denmark $464.190B 33.48
Johnson & Johnson (JNJ) United States $345.687B 14.02
AbbVie (ABBV) United States $303.100B 15.95
Merck (MRK) United States $251.749B 16.73
AstraZeneca (AZN) United Kingdom $199.805B 17.00
Novartis AG (NVS) Switzerland $197.798B 13.15
Sanofi (SNY) $120.547B 10.92
Innoviva (INVA) United States $1.122B 9.34